Capricor Therapeutics CAPR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$114.59M-108% | -$105.04M-160% | -$81.99M-140% | -$69.98M-150% | -$55.06M-126% | ||
| $2.02M+34.6% | $1.89M+32.5% | $1.76M+29.8% | $1.63M+28.0% | $1.5M+28.1% | ||
| $17.4M+45.3% | $16.97M+73.8% | $15.42M+65.3% | $13.48M+49.8% | $11.98M+41.6% | ||
| $1.59M-51.3% | $5.98M+208% | $5.48M— | $4.87M— | $3.26M— | ||
| $3.17M+1,060% | $4.09M+793% | $1.79M+8,119% | $367.58K+20.6% | $273.11K+8.9% | ||
| —— | —— | —— | —— | —— | ||
| -$92.63M-105% | -$69.81M-74.5% | -$61.04M-65.9% | -$52.99M-56.1% | -$45.16M-45.3% | ||
| $7.13M+390% | $2.9M+149% | $1.73M+39.8% | $1.68M+12.3% | $1.45M-7.5% | ||
| -$81.05M+2.1% | $97.48M+184% | -$68.99M— | -$82.94M— | -$82.79M— | ||
| $238.45M+58.9% | $237.03M+55.6% | $80.92M-14.5% | $148.12M+435% | $150.08M+440% | ||
| $250.31M+66.3% | $248.89M+62.9% | $81.16M-14.4% | $148.48M+435% | $150.53M+440% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$59.83K— | -$10.31M— | —— | —— | —— | ||
| $1.59M-51.3% | $5.98M+208% | $5.48M— | $4.87M— | $3.26M— | ||
| $3.17M+1,060% | $4.09M+793% | $1.79M+8,119% | $367.58K+20.6% | $273.11K+8.9% | ||
| $1.37M+2,643% | $715.46K+1,614% | $327.27K+892% | -$60.75K-92.4% | -$54.01K-93.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $257.46K— | ||
| $17.4M+45.3% | $16.97M+73.8% | $15.42M— | $13.48M— | $11.98M— | ||
| —— | —— | —— | —— | —— | ||
| $1.06M+89.2% | $383.54K+3.1% | $629.46K+112% | $670.82K+10.1% | $560.65K-18.3% | ||
| —— | $3.05M— | $2.28M— | $1.52M— | $761.43K— | ||
| -$99.76M-114% | -$72.72M-76.7% | -$62.77M-65.1% | -$54.68M-54.3% | -$46.62M-42.8% | ||
| -$99.76M-114% | -$72.72M-76.7% | -$62.77M-65.1% | -$54.68M-54.3% | -$46.62M-42.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Capricor Therapeutics generate?
- Capricor Therapeutics (CAPR) generated -$92.6M in operating cash flow over the trailing twelve months.
- What is Capricor Therapeutics's free cash flow?
- After $7.1M of capital expenditures, Capricor Therapeutics's free cash flow was -$99.8M over the trailing twelve months, down 114.0% year over year.
- Where does Capricor Therapeutics's cash flow data come from?
- Every line is extracted from Capricor Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.